History

MOTS-c was discovered in 2015 by a team led by Changhan Lee in the laboratory of Pinchas Cohen at the USC Leonard Davis School of Gerontology, with the founding study published in Cell Metabolism in March 2015. It was notable as one of only a handful of known mitochondrial-derived peptides, encoded by a short reading frame inside the mitochondrial 12S rRNA gene. Early research showed it promotes metabolic homeostasis, activates AMPK, and reduces insulin resistance and obesity in mice, leading to its description as a "mitokine." Human therapeutic use remains investigational.

MOTS-c is one of the most-hyped “exercise in a vial” peptides, and the underlying biology is genuinely interesting. But the human evidence that it does anything useful is, as of mid-2026, essentially absent.

What it is

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded not by your nuclear DNA but by a short reading frame inside the mitochondrial genome. It was discovered in 2015 by Changhan Lee, Pinchas Cohen, and colleagues at USC and reported in Cell Metabolism. In cell and animal models it activates AMPK — a central “energy-sensing” enzyme — and can move to the cell nucleus to influence gene expression under metabolic stress. It is sometimes grouped with other mitochondrial-derived peptides such as humanin.

The claims

Marketing and clinic websites pitch MOTS-c as an “exercise mimetic” that improves insulin sensitivity, boosts fat burning, reverses age-related metabolic decline, increases endurance, and promotes longevity. The story is that working muscle releases MOTS-c, blood levels fall with age, and supplementing it recreates the metabolic benefits of training without the training.

What the evidence actually shows

The preclinical data are real and reasonably strong. In mice, MOTS-c improves insulin sensitivity, protects against diet-induced obesity, shifts metabolism toward fat oxidation, and reproduces several adaptations of aerobic exercise. Human work, however, is almost entirely observational: studies report that plasma MOTS-c correlates (sometimes) with age or metabolic markers. That tells us nothing about whether injecting it helps a person.

Interventional human evidence is the missing piece. The closest thing to a clinical program came from CohBar, which tested CB4211 — an engineered analog of MOTS-c, not MOTS-c itself — in an early-phase (Phase 1a/1b) trial. The company reported topline results describing the compound as well-tolerated with some movement in liver enzymes and glucose, but it later suspended the program after deciding the formulation was unsuitable for further development, and CohBar was absorbed into another company (TuHURA Biosciences) in late 2023. No peer-reviewed human trial of MOTS-c itself has demonstrated that it improves insulin sensitivity, body composition, or any clinical outcome. A recurring practical obstacle is delivery: these peptides have poor stability, low bioavailability, and very short half-lives. In short — promising mechanism, robust rodent data, no proven human benefit.

Legal and regulatory status

MOTS-c is not approved by the FDA (or any comparable regulator) for any use. It is not a dietary supplement. Material sold online is unapproved and unregulated, with no guarantee of identity, purity, or dose.

It is also banned in sport. The World Anti-Doping Agency lists MOTS-c by name as a prohibited substance under Section S4.4 (Metabolic Modulators), subsection 4.4.1, Activators of AMP-activated protein kinase (AMPK) — prohibited at all times, in and out of competition. Per USADA, no therapeutic use exemption is available because there is no approved therapeutic use.

Safety

There is no completed, published clinical trial of MOTS-c itself, so the honest answer is that the safety profile in humans is unknown — including any long-term risk. Reported effects from self-experimenters (not controlled data) include rapid or irregular heartbeat, injection-site irritation, insomnia, and fever. Because supply is unregulated, contamination and mislabeling are additional, real risks separate from the molecule itself.

Bottom line

MOTS-c sits on a strong scientific foundation in animals and a near-empty one in humans. It may eventually prove useful for metabolic disease, but right now it is an experimental, unapproved, WADA-banned compound with no demonstrated human benefit and no established safety. Anyone treating it as a proven metabolic or longevity therapy is far ahead of the evidence. Nothing here is medical advice.

Evidence grade: Animal only.